国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
JOURNAL OF INTERNATIONAL ONCOLOGY
2008年
9期
711-713
,共3页
徐志渊%林连兴%张晓平%李忆璇
徐誌淵%林連興%張曉平%李憶璇
서지연%림련흥%장효평%리억선
鼻咽肿瘤%放射疗法%辐射损伤%预后
鼻嚥腫瘤%放射療法%輻射損傷%預後
비인종류%방사요법%복사손상%예후
Nasopharyngeal neoplasms%Radiotherapy%Radiation injuries%Prognosis
目的 探讨超分割放疗治疗鼻咽癌的疗效和并发症情况.方法 对283例鼻咽癌患者采用超分割放疗治疗,部分病例加用5-氟尿嘧啶加顺铂或卡铂方案化疗,放疗采用60Co-γ线外照射,每次1.2 Gy,每天2次,每周5 d,间隔≥6 h,全疗程鼻咽中位放疗剂量72 Gy,颈部中位放疗剂量68.4 Gy.结果 放疗过程中黏膜反应≥3级的病例占12.4%,放化疗结束时完全缓解率为93.6%,1年生存率为93.6%,2年生存率82.7%,5年生存率为60.1%.结论 超分割放疗患者能耐受,疗效好,为鼻咽癌患者提供了一种可能有效的治疗选择,其确切疗效有待大规模临床试验验证.
目的 探討超分割放療治療鼻嚥癌的療效和併髮癥情況.方法 對283例鼻嚥癌患者採用超分割放療治療,部分病例加用5-氟尿嘧啶加順鉑或卡鉑方案化療,放療採用60Co-γ線外照射,每次1.2 Gy,每天2次,每週5 d,間隔≥6 h,全療程鼻嚥中位放療劑量72 Gy,頸部中位放療劑量68.4 Gy.結果 放療過程中黏膜反應≥3級的病例佔12.4%,放化療結束時完全緩解率為93.6%,1年生存率為93.6%,2年生存率82.7%,5年生存率為60.1%.結論 超分割放療患者能耐受,療效好,為鼻嚥癌患者提供瞭一種可能有效的治療選擇,其確切療效有待大規模臨床試驗驗證.
목적 탐토초분할방료치료비인암적료효화병발증정황.방법 대283례비인암환자채용초분할방료치료,부분병례가용5-불뇨밀정가순박혹잡박방안화료,방료채용60Co-γ선외조사,매차1.2 Gy,매천2차,매주5 d,간격≥6 h,전료정비인중위방료제량72 Gy,경부중위방료제량68.4 Gy.결과 방료과정중점막반응≥3급적병례점12.4%,방화료결속시완전완해솔위93.6%,1년생존솔위93.6%,2년생존솔82.7%,5년생존솔위60.1%.결론 초분할방료환자능내수,료효호,위비인암환자제공료일충가능유효적치료선택,기학절료효유대대규모림상시험험증.
Objective To approach the therapeutic effects and complication of hyperfractionated radio-therapy for nasopharyngeal carcinoma. Methods From January 2000 to November 2002,283 patients with na-sopharyngeal carcinoma were treated with hyperfraetionated radiotherapy. For hyperfractionated radiotherapy,γ-ray from 60Co was performed and two fractions of 1.2 Gy were given daily,with an interval of≥6 h,5 days per week to a median dose of 72 Gy for nasopharynx and 68.4 Gy for neck. For some patients, carboplatin or cispla-tin and 5-fluorouracil were transfused. Results The incidence rate of≥3 grade acute mueositis was 12. 4%.The complete remission rate after treatment was 93.6%. The 1,2 and 5 year survival rate was 93.6% ,82. 7%and 60. 1% respectively. Conclusion patients treated with hyperfractionated radiotherapy have good tolerance and therapeutic effect. It provids a treatment means for nasopharyngeal carcinoma. But it must be validated by the large-scale clinical trials.